Analyst Stephen Baxter of Wells Fargo maintained a Sell rating on Oscar Health, reducing the price target to $11.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Stephen Baxter has given his Sell rating due to a combination of factors including Oscar Health’s recent financial performance and future market dynamics. Despite Oscar Health’s potential to gain market share in 2026, the company’s ability to improve its medical loss ratio (MLR) remains uncertain, as the anticipated improvements are offset by lower prior year development. This leads to a cautious outlook on the company’s profitability improvements.
Additionally, the decision to lower the price target to $11 reflects the increased likelihood of subsidy expirations, influenced by recent political developments. While there are initiatives to reduce operating expenses, the overall financial outlook remains challenging, with revenue estimates increasing due to market share gains but offset by rising MLR. These factors contribute to the Sell rating, as the potential risks outweigh the expected benefits.
According to TipRanks, Baxter is an analyst with an average return of -2.5% and a 41.81% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Centene, Molina Healthcare, and Elevance Health.
In another report released on November 7, UBS also maintained a Sell rating on the stock with a $12.00 price target.